根据凯斯西储大学的一项研究，糖尿病药物中的 Semaglutide 可能会降低阿片类药物过量的风险。 Semaglutide in diabetes drugs may reduce opioid overdose risk, per a study at Case Western Reserve University.

凯斯西储大学的一项研究表明，糖尿病药物 Ozempic 和 Wegovy 中的活性成分 semaglutide 可能会显着降低 2 型糖尿病和阿片类药物使用障碍患者服用阿片类药物过量的风险。 A study from Case Western Reserve University indicates that semaglutide, the active ingredient in diabetes drugs Ozempic and Wegovy, may significantly reduce the risk of opioid overdose in patients with type 2 diabetes and opioid use disorder. 研究人员分析了近33,000名患者的数据, 发现服用西马格卢提德与其他糖尿病药物相比, 服用过量药物的风险明显降低. Analyzing data from nearly 33,000 patients, researchers found a notable decrease in overdose risk among those taking semaglutide compared to other diabetes medications. 有必要进一步进行临床试验,以证实这些调查结果。 Further clinical trials are necessary to confirm these findings.